Biomarin Pharmaceutical (BMRN) Common Equity (2009 - 2026)

Biomarin Pharmaceutical has disclosed Common Equity across 18 years of filings, most recently posting $6.2 billion for Q1 2026.

• Quarterly Common Equity rose 7.23% year-over-year to $6.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 billion (up 7.23% YoY) and the FY2025 annual result came in at $6.1 billion, up 7.58% from the prior year.
• Common Equity improved to $6.2 billion in Q1 2026, from $6.1 billion in the prior quarter.
• Over five years, Common Equity peaked at $6.2 billion in Q1 2026 and troughed at $4.4 billion in Q1 2022.
• A 5-year average of $5.2 billion and a median of $5.1 billion in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity increased 5.39% — and 2024, when it advanced 14.27%.
• Tracing BMRN's Common Equity over 5 years: stood at $4.6 billion in 2022, then gained by 7.57% to $5.0 billion in 2023, then advanced by 14.27% to $5.7 billion in 2024, then grew by 7.58% to $6.1 billion in 2025, then increased by 2.06% to $6.2 billion in 2026.
• Business Quant data shows BMRN's Common Equity at $6.2 billion in Q1 2026, $6.1 billion in Q4 2025, and $6.1 billion in Q3 2025.